Press releasehttps://gmedinnovations.com/wp-content/uploads/2020/11/G-Medical-Update-NASDAQ-Initial-Public-Offering.pdf
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%